| Long-term outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI-I) trial. | |
| | |
MedLine Citation:
|
PMID: 10080463 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: This study sought to compare the two-year outcome after primary percutaneous coronary angioplasty or thrombolytic therapy for acute myocardial infarction. BACKGROUND: Primary angioplasty, that is, angioplasty without antecedent thrombolytic therapy, has been shown to be an effective reperfusion modality for patients suffering an acute myocardial infarction. This report reviews the two-year clinical outcome of patients randomized in the Primary Angioplasty in Myocardial Infarction trial. METHODS: At 12 clinical centers, 395 patients who presented within 12 h of the onset of myocardial infarction were randomized to undergo primary angioplasty (195 patients) or to receive tissue-type plasminogen activator (t-PA) (200 patients) followed by conservative care. Patients were followed by physician visits, phone call, letter and review of hospital records for any hospital admission at one month, six months, one year and two years. RESULTS: At two years, patients undergoing primary angioplasty had less recurrent ischemia (36.4% vs. 48% for t-PA, p = 0.026), lower reintervention rates (27.2% vs. 46.5% for t-PA, p < 0.0001) and reduced hospital readmission rates (58.5% vs. 69.0% for t-PA, p = 0.035). The combined end point of death or reinfarction was 14.9% for angioplasty versus 23% for t-PA, p = 0.034. Multivariate analysis found angioplasty to be independently predictive of a reduction in death, reinfarction or target vessel revascularization (p = 0.0001). CONCLUSIONS: The initial benefit of primary angioplasty performed by experienced operators is maintained over a two-year follow-up period with improved infarct-free survival and reduced rate of reintervention. |
| | |
Authors:
|
C M Nunn; W W O'Neill; D Rothbaum; G W Stone; J O'Keefe; P Overlie; B Donohue; L Grines; K F Browne; R E Vlietstra; T Catlin; C L Grines |
Related Documents
:
|
8970403 - Thrombolytic therapy for patients with prior percutaneous transluminal coronary angiopl... 2016483 - Total coronary occlusion: a different animal? 15912253 - The transsylvian trans-limen insular approach to the crural, ambient and interpeduncula... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 33 ISSN: 0735-1097 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 1999 Mar |
Date Detail:
|
Created Date: 1999-03-30 Completed Date: 1999-03-30 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 640-6 Citation Subset: AIM; IM |
Affiliation:
|
Division of Cardiology, Waikato Hospital, Hamilton, New Zealand. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioplasty, Transluminal, Percutaneous Coronary* Coronary Angiography Female Fibrinolytic Agents / administration & dosage, therapeutic use Follow-Up Studies Humans Infusions, Intravenous Male Middle Aged Myocardial Infarction / radiography, therapy* Prospective Studies Recurrence Tissue Plasminogen Activator / administration & dosage, therapeutic use Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Th...
Next Document: The relationship between periprocedural myocardial infarction and subsequent target vessel revascula...